Keyword Search:


Bookmark and Share

Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT

Ahmad Saad, Fathinul Fikri and Kroiss, Alexander and Azman, Ahmad Zaid Fattah and Hussein, Zanariah and Lau, Eddie Wing Fai and Uprimny, Christian and Donnemiller, Eveline and Kendler, Dorota and Nordin, Abdul Jalil and Virgolini, Irene J. (2014) Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma (PCC/PGL) using 18F-FDG PET/CT. Acta Radiologica, 55 (5). pp. 631-640. ISSN 0284-1851; ESSN: 1600-0455

[img] PDF (Abstract)
38Kb

Official URL: http://acr.sagepub.com/content/55/5/631.abstract

Abstract

Background: To our knowledge, data are lacking on the role of 18F-FDG PET/CT in the localization and prediction of neuroendocrine tumors, in particular the pheochromocytoma/paraganglioma (PCC/PGL) group. Purpose: To evaluate the role of 18F-FDG PET/CT in localizing and predicting the malignant potential of PCC/PGL. Material and Methods: Twenty-three consecutive patients with a history of PCC/PGL, presenting with symptoms related to catecholamine excess, underwent 18F-FDG PET/CT. Final confirmation of the diagnosis was made using the composite references. PET/CT findings were analyzed on a per-lesion basis and a per-patient basis. Tumor SUVmax was analyzed to predict the dichotomization of patient endpoints for the local disease and metastatic groups. Results: We investigated 23 patients (10 men, 13 women) with a mean age of 46.43±3.70 years. Serum catecholamine levels were elevated in 82.60% of these patients. There were 136 sites (mean SUVmax: 16.39±3.47) of validated disease recurrence. The overall sensitivities for diagnostic CT, FDG PET, and FDG PET/CT were 86.02%, 87.50%, and 98.59%, respectively. Based on the composite references, 39.10% of patients had local disease. There were significant differences in the SUVmax distribution between the local disease and metastatic groups; a significant correlation was noted when a SUVmax cut-off was set at 9.2 (P<0.05). Conclusion: In recurrent PCC/PGL, diagnostic 18F-FDG PET/CT is a superior tool in the localization of recurrent tumors. Tumor SUVmax is a potentially useful predictor of malignant tumor potential.

Item Type:Article
Keyword:18F-FDG PET/CT; Malignant potential; Neuroendocrine; Pheochromocytoma/paraganglioma; Predictor; Recurrence; SUVmax
Faculty or Institute:Centre For Diagnostic Nuclear Imaging
Faculty of Medicine and Health Science
Publisher:The Foundation Acta Radiologica
DOI Number:10.1177/0284185113504330
Altmetrics:http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1177/0284185113504330
ID Code:34396
Deposited By: Nurul Ainie Mokhtar
Deposited On:15 Sep 2016 15:13
Last Modified:15 Sep 2016 15:13

Repository Staff Only: Edit item detail